Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.

Weimin WangXiang SongYing LouLiying DuDa-Long Zhu Zhiguang Zhou

Published in: Diabetes, obesity & metabolism (2022)

The immunogenicity profiles of LY IGlar and IGlar are similar, with low levels of anti-insulin antibodies observed for both insulins. No association was observed between antibody levels or TEAR status and clinical outcomes.

Keyphrases

glycemic control
type diabetes
weight loss
skeletal muscle
cardiovascular risk factors